Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase […]
CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating
Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used
Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment Read More »
Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia 18 February 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food and Drug Administration (FDA) under the Drug Development Tool
Cambridge Cognition Launches In-House Rater Training Digital Measures that Matter Cambridge Cognition is excited to announce a new service that will help transform the quality and efficiency of brain health research. Our new Rater Training service combines with our existing digital tools to create a more streamlined and accurate way to conduct clinical studies focused
Cambridge Cognition Launches In-House Rater Training Read More »
Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical
Cambridge Cognition Highlights Positive CANTAB® Results in research by Bristol Myers Squibb Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III
Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK. The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital
We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our
Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI). The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive
